NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jul 01 04:00PM ET
28.43
Dollar change
-0.33
Percentage change
-1.15
%
IndexRUT P/E- EPS (ttm)-3.82 Insider Own7.49% Shs Outstand93.53M Perf Week-8.11%
Market Cap2.66B Forward P/E- EPS next Y-4.69 Insider Trans-2.10% Shs Float86.67M Perf Month-6.82%
Enterprise Value1.44B PEG- EPS next Q-1.10 Inst Own104.81% Short Float11.91% Perf Quarter-15.24%
Income-328.25M P/S7398.13 EPS this Y-22.35% Inst Trans2.18% Short Ratio11.33 Perf Half Y-47.27%
Sales0.36M P/B2.12 EPS next Y-3.84% ROA-28.06% Short Interest10.32M Perf YTD-44.40%
Book/sh13.41 P/C2.09 EPS next 5Y2.12% ROE-30.84% 52W High62.53 -54.53% Perf Year-34.60%
Cash/sh13.61 P/FCF- EPS past 3/5Y-9.67% -12.11% ROIC-25.29% 52W Low24.10 17.97% Perf 3Y44.98%
Dividend Est.- EV/EBITDA- Sales past 3/5Y-1.22% - Gross Margin-796.40% Volatility3.95% 3.63% Perf 5Y56.12%
Dividend TTM- EV/Sales3998.68 EPS Y/Y TTM-1.20% Oper. Margin-104467.87% ATR (14)1.22 Perf 10Y-
Dividend Ex-Date- Quick Ratio22.53 Sales Y/Y TTM-100.00% Profit Margin-90928.53% RSI (14)33.94 Recom1.06
Dividend Gr. 3/5Y- - Current Ratio22.53 EPS Q/Q-12.26% SMA20-8.63% Beta0.25 Target Price72.67
Payout- Debt/Eq0.04 Sales Q/Q- SMA50-9.48% Rel Volume0.61 Prev Close28.76
Employees437 LT Debt/Eq0.04 EarningsMay 08 AMC SMA200-32.63% Avg Volume910.69K Price28.43
IPOJul 18, 2018 Option/ShortYes / Yes EPS/Sales Surpr.-10.54% 162.55% Trades Volume556,256 Change-1.15%
Date Action Analyst Rating Change Price Target Change
Mar-25-25Initiated Stifel Buy $60
Feb-11-25Initiated TD Cowen Buy
Feb-04-25Initiated Wolfe Research Peer Perform
Jan-22-25Upgrade Jefferies Hold → Buy $55
Mar-06-24Initiated Citigroup Buy $68
Jan-16-24Initiated Morgan Stanley Overweight $50
Dec-21-23Initiated Jefferies Hold $35
Nov-20-23Resumed JP Morgan Overweight $35
Oct-24-23Resumed Cantor Fitzgerald Overweight $52 → $50
Aug-31-23Initiated Oppenheimer Outperform $40
Jun-30-25 04:05PM
Jun-16-25 08:00AM
Jun-10-25 04:29PM
May-23-25 08:00AM
May-15-25 04:05PM
04:05PM Loading…
May-12-25 04:05PM
May-09-25 01:01PM
08:48AM
May-08-25 05:40PM
04:05PM
May-07-25 09:57AM
Apr-11-25 08:00AM
Apr-10-25 05:04PM
Apr-02-25 02:15PM
Mar-27-25 04:05PM
04:36PM Loading…
Mar-10-25 04:36PM
Feb-27-25 04:05PM
03:24PM
Feb-26-25 07:26AM
Feb-24-25 08:30AM
Feb-20-25 04:05PM
Feb-10-25 04:44PM
Feb-06-25 04:35PM
Feb-05-25 04:57PM
Jan-29-25 05:37PM
Jan-21-25 04:10PM
Jan-17-25 11:12AM
Jan-10-25 05:15PM
07:00AM
Jan-06-25 08:00AM
08:00AM Loading…
Dec-16-24 08:00AM
Dec-10-24 08:44PM
06:22AM
Dec-09-24 08:00AM
Nov-15-24 09:00AM
Nov-14-24 04:05PM
Nov-13-24 02:18AM
Nov-12-24 04:07PM
04:05PM
Nov-11-24 04:05PM
Oct-17-24 03:09PM
Oct-16-24 08:00AM
Oct-10-24 04:40PM
08:57AM
Oct-09-24 05:56PM
Oct-08-24 11:55PM
04:01PM
Sep-26-24 04:05PM
Sep-12-24 07:00PM
Sep-10-24 04:40PM
Sep-05-24 01:07AM
Sep-02-24 06:05PM
Aug-29-24 04:05PM
Aug-28-24 07:01PM
Aug-14-24 07:02PM
Aug-12-24 04:05PM
Aug-08-24 09:57PM
06:00PM
04:05PM
08:30AM
Aug-01-24 10:01AM
Jul-26-24 07:00PM
Jul-18-24 04:05PM
Jul-12-24 07:01PM
Jul-10-24 07:29PM
Jun-26-24 07:00PM
02:11PM
Jun-18-24 04:30PM
Jun-12-24 02:38AM
Jun-10-24 06:35PM
Jun-03-24 12:16PM
12:00PM
12:00PM
May-31-24 02:46AM
May-30-24 04:05PM
May-22-24 08:00AM
May-16-24 05:23PM
May-13-24 10:53AM
May-10-24 05:38PM
05:03PM
12:47PM
May-09-24 08:55PM
05:35PM
05:03PM
04:05PM
May-08-24 04:05PM
May-07-24 08:55AM
May-02-24 04:05PM
Apr-11-24 04:05PM
Mar-28-24 08:10AM
Mar-26-24 07:01PM
Mar-22-24 07:02PM
07:02PM
Mar-21-24 02:32AM
Mar-20-24 11:46AM
05:14AM
Mar-19-24 04:48PM
04:03PM
08:08AM
06:16AM
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Betz Stephen F.Chief Scientific OfficerJun 12 '25Option Exercise3.3088,170291,078197,196Jun 16 04:48 PM
Betz Stephen F.Chief Scientific OfficerJun 12 '25Sale32.2397,4833,141,87799,713Jun 16 04:48 PM
STEPHEN BETZOfficerJun 12 '25Proposed Sale32.3397,4833,151,625Jun 12 04:19 PM
Struthers Richard ScottPresident & CEOApr 02 '25Option Exercise1.9181,270155,226410,417Apr 04 04:30 PM
Pizzuti DanaChief Med and Dev OfficerMar 19 '25Sale34.202,51586,02172,233Mar 21 06:34 PM
Knight Jeff E.Chief Operating OfficerMar 19 '25Sale34.207,162244,96487,491Mar 21 06:33 PM
Betz Stephen F.Chief Scientific OfficerMar 19 '25Sale34.205,770197,353108,588Mar 21 06:32 PM
Struthers Richard ScottPresident & CEOMar 19 '25Sale34.2017,338593,017329,147Mar 21 06:31 PM
Pizzuti DanaChief Med and Dev OfficerFeb 03 '25Option Exercise16.895,00084,45036,748Feb 05 04:30 PM
Pizzuti DanaChief Med and Dev OfficerFeb 03 '25Sale39.075,000195,35031,748Feb 05 04:30 PM
DANA J PIZZUTIOfficerFeb 03 '25Proposed Sale39.075,000195,372Feb 03 04:11 PM
Pizzuti DanaChief Med and Dev OfficerJan 03 '25Option Exercise16.8915,000253,35044,248Jan 07 04:30 PM
Pizzuti DanaChief Med and Dev OfficerJan 07 '25Option Exercise19.642,50049,10031,748Jan 07 04:30 PM
Pizzuti DanaChief Med and Dev OfficerJan 03 '25Sale52.0915,000781,35029,248Jan 07 04:30 PM
DANA J PIZZUTIOfficerJan 03 '25Proposed Sale52.0915,000781,323Jan 03 04:12 PM
Betz Stephen F.Chief Scientific OfficerDec 16 '24Option Exercise1.912,3314,45271,358Dec 18 04:30 PM
Struthers Richard ScottPresident & CEODec 02 '24Sale57.5710,000575,700100,000Dec 04 04:30 PM
Struthers Richard ScottOfficerDec 02 '24Proposed Sale57.2710,000572,700Dec 02 04:06 PM
Knight Jeff E.Chief Operating OfficerNov 22 '24Sale56.5250128,31751,653Nov 26 04:30 PM
Pizzuti DanaChief Med and Dev OfficerOct 03 '24Option Exercise16.8914,375242,79442,882Oct 07 07:55 AM
Pizzuti DanaChief Med and Dev OfficerOct 03 '24Sale54.6314,375785,30628,507Oct 07 07:55 AM
DANA J PIZZUTIOfficerOct 03 '24Proposed Sale54.6314,375785,322Oct 03 04:08 PM
Wilson MarcCFOSep 26 '24Option Exercise15.2925,000382,250136,092Sep 30 05:01 PM
Wilson MarcCFOSep 26 '24Sale51.1125,0001,277,750111,092Sep 30 05:01 PM
MARC WILSONOfficerSep 26 '24Proposed Sale51.1025,0001,277,625Sep 26 04:06 PM
Betz Stephen F.Chief Scientific OfficerSep 10 '24Sale51.501,03553,30268,576Sep 12 04:30 PM
Betz Stephen F.OfficerSep 10 '24Proposed Sale51.501,03553,301Sep 10 12:11 PM
Betz Stephen F.Chief Scientific OfficerAug 26 '24Sale53.193,000159,57069,611Aug 28 04:31 PM
Betz Stephen F.OfficerAug 26 '24Proposed Sale53.193,000159,570Aug 26 01:16 PM
Betz Stephen F.Chief Scientific OfficerAug 12 '24Sale47.683,000143,04072,611Aug 14 04:30 PM
Betz Stephen F.OfficerAug 12 '24Proposed Sale47.683,000143,050Aug 12 11:35 AM
Betz Stephen F.Chief Scientific OfficerJul 25 '24Sale53.433,000160,29075,611Jul 26 04:38 PM
Wilson MarcCFOJul 25 '24Option Exercise9.2819,056176,840130,148Jul 26 04:24 PM
Wilson MarcCFOJul 25 '24Sale53.8819,0561,026,737111,092Jul 26 04:24 PM
Knight Jeff E.Chief Operating OfficerJul 15 '24Option Exercise22.5926,073589,11678,653Jul 17 05:35 PM
Knight Jeff E.Chief Operating OfficerJul 15 '24Sale55.0027,0001,485,00051,653Jul 17 05:35 PM
Wilson MarcCFOJul 15 '24Option Exercise20.0225,000500,500136,092Jul 17 05:14 PM
Wilson MarcCFOJul 15 '24Sale55.0025,0001,375,000111,092Jul 17 05:14 PM
Betz Stephen F.Chief Scientific OfficerJul 10 '24Sale48.553,000145,65078,611Jul 12 04:30 PM
Hassard JamesChief Commercial OfficerJul 05 '24Option Exercise19.7315,000295,95044,259Jul 09 06:04 PM
Hassard JamesChief Commercial OfficerJul 05 '24Sale44.0815,000661,20029,259Jul 09 06:04 PM
Pizzuti DanaChief Med and Dev OfficerJul 03 '24Option Exercise16.8914,375242,79442,882Jul 05 04:30 PM
Pizzuti DanaChief Med and Dev OfficerJul 03 '24Sale44.8714,375645,00628,507Jul 05 04:30 PM